Matthew Westercamp1, Walter Jaoko, Supriya Mehta, Pauline Abuor, Perez Siambe, Robert C Bailey. 1. *Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago, Chicago, IL; †Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya; and ‡Nyanza Reproductive Health Society (NRHS), Kisumu, Kenya.
Abstract
BACKGROUND: Three randomized controlled trials showed that voluntary medical male circumcision (VMMC) reduces the risk of female-to-male HIV transmission by approximately 60%. However, data from communities where VMMC programs have been implemented are needed to assess changes in circumcision prevalence and whether men and women compensate for perceived reductions in risk by increasing their HIV risk behaviors. METHODS: Scale-up of free VMMC began in Kisumu, Kenya in 2008. Between 2009 and 2013, a sequence of 3 unlinked cross-sectional surveys were conducted. All individuals 15-49 years of age residing in randomly selected households were interviewed and offered HIV testing. Male circumcision status was confirmed by examination. Design-adjusted bivariate comparisons and multivariable analyses were used for statistical inference. RESULTS: The prevalence of male circumcision increased from 32% (95% CI: 26% to 38%) in 2009 to 60% (95% CI: 56% to 63%) in 2013. The adjusted prevalence ratio of HIV and genital ulcer disease in circumcised compared with uncircumcised men was 0.48 (95% CI: 0.36 to 0.66) and 0.51 (95% CI: 0.37 to 0.69), respectively. There was no association between circumcision status and sexual behaviors, HIV knowledge, or indicators of risk perception. CONCLUSIONS: The conditions necessary for the VMMC program to have a significant public health impact are present in Kisumu, Kenya. Between 2009 and 2013, circumcision prevalence increased from 30% to 60%; HIV prevalence in circumcised men was half that of uncircumcised men, and there was no or minimal sexual risk compensation.
BACKGROUND: Three randomized controlled trials showed that voluntary medical male circumcision (VMMC) reduces the risk of female-to-male HIV transmission by approximately 60%. However, data from communities where VMMC programs have been implemented are needed to assess changes in circumcision prevalence and whether men and women compensate for perceived reductions in risk by increasing their HIV risk behaviors. METHODS: Scale-up of free VMMC began in Kisumu, Kenya in 2008. Between 2009 and 2013, a sequence of 3 unlinked cross-sectional surveys were conducted. All individuals 15-49 years of age residing in randomly selected households were interviewed and offered HIV testing. Male circumcision status was confirmed by examination. Design-adjusted bivariate comparisons and multivariable analyses were used for statistical inference. RESULTS: The prevalence of male circumcision increased from 32% (95% CI: 26% to 38%) in 2009 to 60% (95% CI: 56% to 63%) in 2013. The adjusted prevalence ratio of HIV and genital ulcer disease in circumcised compared with uncircumcised men was 0.48 (95% CI: 0.36 to 0.66) and 0.51 (95% CI: 0.37 to 0.69), respectively. There was no association between circumcision status and sexual behaviors, HIV knowledge, or indicators of risk perception. CONCLUSIONS: The conditions necessary for the VMMC program to have a significant public health impact are present in Kisumu, Kenya. Between 2009 and 2013, circumcision prevalence increased from 30% to 60%; HIV prevalence in circumcised men was half that of uncircumcised men, and there was no or minimal sexual risk compensation.
Authors: Supriya D Mehta; Stephen Moses; Kawango Agot; Ian Maclean; Elijah Odoyo-June; Hong Li; Robert C Bailey Journal: J Infect Dis Date: 2013-07-30 Impact factor: 5.226
Authors: Xiangrong Kong; Godfrey Kigozi; Fred Nalugoda; Richard Musoke; Joseph Kagaayi; Carl Latkin; Robert Ssekubugu; Tom Lutalo; Betty Nantume; Iga Boaz; Maria Wawer; David Serwadda; Ronald Gray Journal: Am J Epidemiol Date: 2012-10-24 Impact factor: 4.897
Authors: Craig R Cohen; Michele Montandon; Adam W Carrico; Stephen Shiboski; Alan Bostrom; Alfredo Obure; Zachary Kwena; Robert C Bailey; Rosemary Nguti; Elizabeth A Bukusi Journal: PLoS One Date: 2009-03-04 Impact factor: 3.240
Authors: Christine L Mattson; Richard T Campbell; Robert C Bailey; Kawango Agot; J O Ndinya-Achola; Stephen Moses Journal: PLoS One Date: 2008-06-18 Impact factor: 3.240
Authors: Carol S Camlin; Alison M El Ayadi; Zachary A Kwena; Willi McFarland; Mallory O Johnson; Torsten B Neilands; Elizabeth A Bukusi; Craig R Cohen Journal: J Acquir Immune Defic Syndr Date: 2017-04-15 Impact factor: 3.731
Authors: Aimee Leidich; Lillian Achiro; Zachary A Kwena; Willi McFarland; Torsten B Neilands; Craig R Cohen; Elizabeth A Bukusi; Carol S Camlin Journal: PLoS One Date: 2018-01-11 Impact factor: 3.240
Authors: Kaitlyn Atkins; Ping Teresa Yeh; Caitlin E Kennedy; Virginia A Fonner; Michael D Sweat; Kevin R O'Reilly; Rachel Baggaley; George W Rutherford; Julia Samuelson Journal: PLoS One Date: 2020-01-13 Impact factor: 3.240
Authors: Lisa P Spees; Kathleen E Wirth; Shreshth Mawandia; Semo Bazghina-Werq; Jenny H Ledikwe Journal: South Afr J HIV Med Date: 2020-12-14 Impact factor: 2.744
Authors: Michelle R Kaufman; Kim H Dam; Kriti Sharma; Lynn M Van Lith; Karin Hatzold; Arik V Marcell; Webster Mavhu; Catherine Kahabuka; Lusanda Mahlasela; Eshan U Patel; Emmanuel Njeuhmeli; Kim Seifert Ahanda; Getrude Ncube; Gissenge Lija; Collen Bonnecwe; Aaron A R Tobian Journal: Clin Infect Dis Date: 2018-04-03 Impact factor: 9.079